Business Context and Reporting Period
This Form 8-K Current Report is filed by DaVita Inc. with a report date of October 31, 2005. The filing discloses the entry into material definitive agreements regarding executive employment and severance arrangements effective in late October and early November 2005.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The financial data provided is limited to specific compensation terms within the disclosed agreements:
- Dennis Kogod (President - West): Annual base salary of $397,500; performance bonus up to 60% of base salary; 20,000 stock options; 5,000 restricted stock units (RSUs).
- Christopher J. Riopelle (Chief Compliance Officer): Annual base salary of $225,000; 2005 performance bonus up to 60% of base salary (subsequent years capped at $135,000); 25,000 stock options; 2,500 RSUs.
- Lori Pelliccioni (Severance): Continued base salary payment from November 13, 2005, through February 12, 2006; partial COBRA reimbursement for three months; acceleration of vesting for 30,000 stock options.
Material Changes
The filing reports the following material changes in corporate personnel and compensation structure:
- New Executive Appointments: Appointment of Dennis Kogod as President - West and Christopher J. Riopelle as Chief Compliance Officer.
- Executive Departure: Termination of Lori Pelliccioni's employment effective November 11, 2005, under a severance agreement.
- Compensation Structure: Implementation of new "at-will" employment terms with specific severance triggers (e.g., one-year salary continuation for Kogod upon termination without cause; two-year continuation for Kogod upon resignation following a change of control).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future business performance. The primary risks and contingencies disclosed relate to the terms of the employment agreements:
- Termination Provisions: Specific financial liabilities arise if executives are terminated without cause or resign for "good cause," triggering salary continuation and bonus payments.
- Non-Compete and Non-Solicit: Both Kogod and Riopelle are subject to one-year post-employment restrictions on competing with DaVita and soliciting employees, patients, physicians, or customers.
- Equity Vesting: Stock options and RSUs are subject to specific vesting schedules (ranging from 3 to 5 years), with accelerated vesting provisions for Pelliccioni upon termination.
Investor Verification Checklist
- Verify the exact vesting schedules and exercise prices for the 20,000 options granted to Kogod and 25,000 options granted to Riopelle.
- Confirm the total cash outflow for Lori Pelliccioni's severance, including the specific base salary amount and COBRA reimbursement calculation.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for detailed definitions of "good cause," "material cause," and "change of control" which dictate severance eligibility.
- Assess the impact of the new executive appointments on the company's operational strategy for the Western region and compliance functions.